Abstract: The present invention relates to recombinant MDV1 viruses and the uses thereof. The invention is particularly suited to vaccinate poultry against avian pathogens.
Abstract: The present invention relates to DEV and the uses thereof. The invention is particularly suited to vaccinate poultry against avian pathogens.
Abstract: The present invention relates recombinant viruses and the uses thereof. More particularly, the invention relates to novel recombinant Marek's disease viruses encoding polypeptide(s) of interest, and their use to express or deliver such polypeptides to animals, particularly poultry. The invention is particularly suited to vaccinate poultry against avian pathogens.
Type:
Grant
Filed:
September 5, 2014
Date of Patent:
January 29, 2019
Assignee:
CEVA SANTE ANIMALE
Inventors:
Motoyuki Esaki, Shuji Saitoh, Takanori Sato
Abstract: The present invention relates to novel immunogenic polypeptides and their use in vaccine compositions. The invention also relates to nucleic acids, vectors and cells which express the polypeptides and the uses thereof. The polypeptides of the invention more specifically comprise an immunogenic domain and a cell membrane addressing domain which is derived from a B5R gene. The invention is particularly suited to produce vaccines for non-human animals, particularly for vaccinating swine against PCV2 infection.
Abstract: The present invention relates to novel recombinant swinepox viruses and their use in vaccine compositions. The recombinant swinepox viruses of the invention are produced 5 by inserting one or more foreign genes into IL-18 binding protein (IL18bp) gene of swinepox virus. The invention is particularly suited to produce swine vaccines, particularly for vaccinating swine against PCV2 infection.
Abstract: The invention relates to a composition containing pheromones comprising a carrier solvent, and to the use thereof for preventing and/or treating the behavioral or medical problems linked to the stress of non-human mammals. The invention also relates to a device for diffusing such a composition into the ambient air, and to a kit comprising said composition.
Abstract: This invention relates to a method of controlling the spread of dirofilariosis, such as for example heartworm, by administering to at least one non-human animal infested with filarioid nematodes such as Dirofilaria spp or susceptible to have been infested with filarioid nematodes such as Dirofilaria spp, an effective dose of a combination of a neonicotinoid compound and a pyrethroid compound.
Abstract: The invention relates to novel veterinary compositions comprising an effective amount of a neonicotinoid compound and an effective amount of a N-arylpyrazole compound. The invention also relates to the use of such compositions for controlling ectoparasites in a non-human mammal.
Abstract: The invention relates to improved methods for protecting non-human animals with triazine compounds by intramuscular or subcutaneous injection(s). The invention can be used with various triazines, such as toltrazuril, in different non-human animals, such as a porcine, an ovine, a bovine, a canine, a feline, or an avian, for protecting them against infectious diseases, such as protozoan disorders.
Type:
Grant
Filed:
December 6, 2013
Date of Patent:
January 30, 2018
Assignee:
CEVA SANTE ANIMALE
Inventors:
Hamadi Karembe, Roman Krejci, Jérôme Guyonnet, Hannelie Cilliers
Abstract: The present invention relates to a parenteral composition comprising an antibiotic and a non-steroidal anti-inflammatory agent in solution in a particular solvent. The composition is intended in particular to be injected in a non-human mammal, in particular a farm animal. It also relates to a method for treating disorders connected with a microbial infection in non-human mammals by injecting said composition.
Type:
Application
Filed:
September 9, 2015
Publication date:
October 26, 2017
Applicant:
CEVA SANTE ANIMALE
Inventors:
Florence GUIMBERTEAU, Anne GENETEAU, Jerome GUYONNET
Abstract: This present invention relates to an antiprolactinic veterinary composition to be administered to ruminants. Said composition comprises at least one antiprolactinic compound which is an agonist of dopamine receptors, and is particularly useful for reducing udder engorgement and/or the reduction of pain after drying off and/or of increasing welfare, and/or of reducing milk leakage in ruminants as well as for preventing new mammary microbial infections, secondary infection, or co-infections in ruminants and mastitis.
Abstract: This present invention relates to an antiprolactinic veterinary composition to be administered to ruminants. Said composition comprises at least one antiprolactinic compound which is an agonist of dopamine receptors, and is particularly useful for promoting a substantial reduction of lactation, mammary involution, and for treating and/or intra-mammary diseases or infections of ruminants.
Abstract: The present invention relates to novel compositions for inducing an immune response in mammals. The composition preferably comprises an antigen and a lipopolysaccharide in an oil-in-water formulation. The invention is particularly suited to vaccinate swine against mycoplasma infections.
Type:
Grant
Filed:
March 7, 2012
Date of Patent:
June 27, 2017
Assignee:
CEVA SANTE ANIMALE
Inventors:
Jerome Thevenon, Ferenc Misak, Miklos Tenk
Abstract: The invention relates to compositions and to the methods of administration thereof. More specifically, it relates to an optimised method for the administration of active agents to non-human mammals by means of topical application of pre-determined doses.
Abstract: The present invention relates to synthetic proteins and the uses thereof. More particularly, the invention relates to synthetic Circovirus type capsid proteins with improved properties. These proteins, or the coding nucleic acids, are useful e.g., to generate antibodies, immunogen compositions, or vaccines. The invention further relates to methods for treating and/or preventing PCV2-associated diseases in mammals using said proteins, nucleic acids or compositions. The invention also relates to compositions and methods for detecting PCV2 in a sample, using the above proteins, nucleic acids, or antibodies.
Type:
Grant
Filed:
August 31, 2012
Date of Patent:
January 24, 2017
Assignee:
Ceva Sante Animale
Inventors:
Zoltan Penzes, Anna Kollar, Marianna Ivok
Abstract: The present invention further relates to ivermectin, most preferably formulated as an implant for administration of pet and domestic animals. These formulations provide long term protection against Dirofilaria parasites, without the risks for secondary adverse events of conventional formulations. Preferred formulations are implants and are administered at least twice a year, once a year, or at least once in 18 months, up to 24 months.
Type:
Grant
Filed:
July 29, 2011
Date of Patent:
May 31, 2016
Assignee:
CEVA SANTE ANIMALE
Inventors:
Patrick Forget, Vassilios Kaltsatos, Stephan Warin
Abstract: The present invention concerns palatable veterinary compositions made from one or more pharmaceutical active ingredients having a smell and/or a taste that is repulsive to animals, and a preparation method for preparing said oral veterinary compositions.
Abstract: The invention relates to a liquid pharmaceutical composition, in the form of a suspension of micronized powder of active substance in an acceptable physiological liquid medium, stabilized over time, for administration via the oral route.